MyoKardia to price IPO of 4,687,500 shares between $15.00 and $17.00

Credit Suisse, Cowen, Wells Fargo, Wedbush Securities assist with deal

By Devika Patel

Knoxville, Tenn., Oct. 19 – MyoKardia, Inc. will sell 4,687,500 common shares in its initial public offering with a 30-day greenshoe of 703,125 additional shares, according to an S-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $91,640,625 of stock for the sale, which was announced Sept. 28.

The shares will be sold at a price expected to fall between $15.00 and $17.00 each.

Existing stockholder Sanofi has indicated an interest in investing up to $25 million.

Credit Suisse Securities (USA) LLC and Cowen and Co. are the bookrunners. Wells Fargo Securities LLC is the lead manager, and Wedbush Securities Inc. is the co-manager.

Proceeds will be used for clinical development, preclinical, discovery and research programs, research and development activities, working capital and other general corporate purposes.

The South San Francisco, Calif., biopharmaceutical company seeks to treat serious and neglected rare cardiovascular diseases. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “MYOK.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.